Exploring the effectiveness of a regional nurse practitioner led, long-acting injectable buprenorphine-based model of care for opioid use disorder

被引:2
|
作者
Strike, Teresa [1 ]
D'Angelo-Kemp, Dante [2 ]
Searby, Adam [3 ,4 ]
机构
[1] Cent Gippsland Hlth, Sale, Vic, Australia
[2] Dante Kemp Consulting Serv, Newcastle, NSW, Australia
[3] Deakin Univ, Inst Hlth Transformat, Sch Nursing & Midwifery, Geelong, Vic, Australia
[4] Deakin Univ, 221 Burwood Hwy, Burwood, Vic, Australia
关键词
buprenorphine; injectable; nurse practitioners; nurse-led clinics; opioid substitution treatment; opioid-related disorders;
D O I
10.1111/inm.13154
中图分类号
R47 [护理学];
学科分类号
1011 ;
摘要
The introduction of long-acting injectable buprenorphine preparations for opioid use disorder has been widely heralded as a breakthrough treatment, with several studies indicating positive results when using these medications. In many locations, nurse practitioners prescribe, administer, and monitor long-acting injectable preparations. The objective of this paper is to explore whether a reduction in dispensed needles and syringes is attributable to increased nurse practitioner prescribing of LAIB. We used a retrospective audit of needles dispensed through the health service needle and syringe program vending machine, and individuals treated with long-acting injectable buprenorphine by the nurse practitioner led model. In addition, we examined potential factors that may influence changes in the number of needles dispensed. Linear regression found that each individual with opioid dependence treated with long-acting injectable buprenorphine was associated with 90 fewer needles dispensed each month (p < 0.001). The nurse practitioner led model of care for individuals with opioid dependence appears to have influenced the number of needles dispensed at the needle and syringe program. Although all confounding factors could not be discounted entirely, such as substance availability, affordability, and individuals obtaining injecting equipment elsewhere, our research indicates that a nurse practitioner led model of treating individuals with opioid use disorder influenced needle and syringe dispensing in the study setting.
引用
收藏
页码:1129 / 1137
页数:9
相关论文
共 32 条
  • [21] Integrating long-acting injectable treatment to improve medication adherence among persons living with HIV and opioid use disorder: study protocol
    Kirsten J. Langdon
    Anthony E. Hitch
    Alexandra B. Collins
    Curt G. Beckwith
    Sara Becker
    Karen Tashima
    Josiah D. Rich
    Addiction Science & Clinical Practice, 18
  • [22] Integrating long-acting injectable treatment to improve medication adherence among persons living with HIV and opioid use disorder: study protocol
    Langdon, Kirsten J.
    Hitch, Anthony E.
    Collins, Alexandra B.
    Beckwith, Curt G.
    Becker, Sara
    Tashima, Karen
    Rich, Josiah D.
    ADDICTION SCIENCE & CLINICAL PRACTICE, 2023, 18 (01)
  • [23] ASSESSING THE SAFETY AND FEASIBILITY OF LONG-ACTING DEPOT OF BUPRENORPHINE IN ADULTS REQUIRING TREATMENT FOR OPIOID USE DISORDER IN NEW SOUTH WALES CUSTODIAL SETTINGS
    White, Bethany
    Haber, Paul S.
    Lintzeris, Nicholas
    Roberts, Jillian
    Cretikos, Michelle
    Mackson, Judith
    Attia, John
    Oldmeadow, Christopher
    Searles, Andrew
    Howard, Mark
    Murrell, Terry
    Doyle, Michael
    Mcentyre, Elizabeth
    Brown, Elizabeth
    Willis, Jennifer
    Dunlop, Adrian J.
    DRUG AND ALCOHOL REVIEW, 2018, 37 : S75 - S75
  • [24] COST-EFFECTIVENESS OF ALPHA-2 ADRENERGIC AGONIST (LOFEXIDINE) AND LONG-ACTING INJECTABLES FOR TREATMENT OF OPIOID USE DISORDER
    Ahmed, N.
    Bishop, L.
    Bornstein, S.
    Nguyen, H.
    VALUE IN HEALTH, 2022, 25 (01) : S111 - S111
  • [25] Physiologically based pharmacokinetic modeling of long-acting extended-release naltrexone in pregnant women with opioid use disorder
    Shenkoya, Babajide
    Gopalakrishnan, Mathangi
    Eke, Ahizechukwu C.
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2024, 13 (11): : 1939 - 1952
  • [26] Treatment satisfaction and patient reported outcomes among people with opioid use disorder participating in an open-label, non-randomised trial of long-acting injectable buprenorphine treatment in Australian custodial settings
    White, Bethany
    Little, Sophia
    Haber, Paul S.
    Roberts, Jillian
    Nolan, Erin
    Lintzeris, Nicholas
    Dunlop, Adrian J.
    DRUG AND ALCOHOL REVIEW, 2025, 44 (02) : 640 - 648
  • [27] Use of a primary care and pharmacy-based model for the delivery of injectable opioid agonist treatment for severe opioid use disorder: a case report
    Wilson, Tyler
    Brar, Rupi
    Sutherland, Christy
    Nolan, Seonaid
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2020, 192 (05) : E115 - E117
  • [28] Recovery From Opioid Use Disorder (OUD) After Monthly Long-acting Buprenorphine Treatment: 12-Month Longitudinal Outcomes From RECOVER, an Observational Study
    Ling, Walter
    Nadipelli, Vijay R.
    Aldridge, Arnie P.
    Ronquest, Naoko A.
    Solem, Caitlyn T.
    Chilcoat, Howard
    Albright, Victoria
    Johnson, Courtney
    Learned, Susan M.
    Mehra, Vishaal
    Heidbreder, Christian
    JOURNAL OF ADDICTION MEDICINE, 2020, 14 (05) : E233 - E240
  • [29] The ORIENT study protocol: imprOving Rural and regIonal accEss to long-acting reversible contraceptioN and medical abortion through nurse-led models of care, Tasksharing and telehealth
    Botfield, Jessica
    Mazza, Danielle
    Subasinghe, Asvini
    Moulton, Jessica
    Hamill, Kellie
    Black, Kirsten
    Tomnay, Jane
    Bateson, Deborah
    McGeechan, Kevin
    Laba, Tracey-Lea
    Norman, Wendy
    AUSTRALIAN JOURNAL OF PRIMARY HEALTH, 2021, 27 (04) : VIII - VIII
  • [30] The post COVID-19 healthcare landscape and the use of long-acting injectable antipsychotics for individuals with schizophrenia and bipolar I disorder: the importance of an integrated collaborative-care approach
    Correll, Christoph U.
    Chepke, Craig
    Gionfriddo, Paul
    Parks, Joe
    Foxworth, Phyllis
    Basu, Anirban
    Brister, Teri S.
    Brown, Dawn
    Clarke, Christopher
    Hassoun, Youssef
    BMC PSYCHIATRY, 2022, 22 (01)